Traditional Alzheimer’s Approach Completely Wrong – Study

Google+ Pinterest LinkedIn Tumblr

A closely watched Alzheimer’s study that tested out a major scientific theory of the disease has left some experts questioning the entire approach.

Many drug makers, including Biogen BIIB, -1.57% and Eisai 4523, -1.69%, which were responsible for last month’s trial, designed their approach around a decades-old theory of the degenerative disease.

But there hasn’t been a lot to show for it, including a number of recent high-profile drug failures. And recent results from a phase 2 trial of Biogen and Eisai’s Alzheimer’s drug BAN2401, though ostensibly positive, may not change the larger picture.

Read more

Chris G. Long

Chis Long is an award winning writer for The San Andreas Times, and various other publications. He lives in Sacramento with his wife and two children.

Write A Comment

%d bloggers like this: